JP2021510682A5 - - Google Patents

Download PDF

Info

Publication number
JP2021510682A5
JP2021510682A5 JP2020536519A JP2020536519A JP2021510682A5 JP 2021510682 A5 JP2021510682 A5 JP 2021510682A5 JP 2020536519 A JP2020536519 A JP 2020536519A JP 2020536519 A JP2020536519 A JP 2020536519A JP 2021510682 A5 JP2021510682 A5 JP 2021510682A5
Authority
JP
Japan
Prior art keywords
ketamine
composition
use according
dose
puffs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020536519A
Other languages
English (en)
Japanese (ja)
Other versions
JP7315556B2 (ja
JP2021510682A (ja
Filing date
Publication date
Priority claimed from EP17461651.6A external-priority patent/EP3505157B1/en
Application filed filed Critical
Publication of JP2021510682A publication Critical patent/JP2021510682A/ja
Publication of JP2021510682A5 publication Critical patent/JP2021510682A5/ja
Application granted granted Critical
Publication of JP7315556B2 publication Critical patent/JP7315556B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020536519A 2017-12-29 2018-09-28 肺投与によるうつ病の処置における使用のための乾燥粉末ケタミン組成物 Active JP7315556B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17461651.6A EP3505157B1 (en) 2017-12-29 2017-12-29 Dry powder ketamine composition for pulmonary administration in treatment-resistant depression
EP17461651.6 2017-12-29
PCT/EP2018/076394 WO2019129397A1 (en) 2017-12-29 2018-09-28 Dry powder ketamine composition for use in the treatment of depression by pulmonary administration

Publications (3)

Publication Number Publication Date
JP2021510682A JP2021510682A (ja) 2021-04-30
JP2021510682A5 true JP2021510682A5 (enExample) 2021-11-04
JP7315556B2 JP7315556B2 (ja) 2023-07-26

Family

ID=60915417

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020536519A Active JP7315556B2 (ja) 2017-12-29 2018-09-28 肺投与によるうつ病の処置における使用のための乾燥粉末ケタミン組成物

Country Status (16)

Country Link
US (3) US20200337999A1 (enExample)
EP (2) EP3505157B1 (enExample)
JP (1) JP7315556B2 (enExample)
KR (2) KR20250024526A (enExample)
CN (1) CN111818912A (enExample)
AU (2) AU2018395791B2 (enExample)
BR (1) BR112020013282A2 (enExample)
CA (1) CA3087090A1 (enExample)
DK (2) DK3505157T3 (enExample)
EA (1) EA202091618A1 (enExample)
ES (2) ES2907692T3 (enExample)
HU (2) HUE058320T2 (enExample)
MX (1) MX2020006900A (enExample)
PL (2) PL3505157T3 (enExample)
PT (2) PT3505157T (enExample)
WO (1) WO2019129397A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3505157B1 (en) 2017-12-29 2021-12-08 Celon Pharma S.A. Dry powder ketamine composition for pulmonary administration in treatment-resistant depression
CN117241039A (zh) 2018-08-28 2023-12-15 华为技术有限公司 帧间预测方法、装置以及视频编码器和视频解码器
EP3628313B1 (en) * 2018-09-28 2025-02-12 Novohale Therapeutics, LLC Ketamine composition for use in a method of treatment of depression by pulmonary administration
CN115418398B (zh) * 2022-08-30 2025-02-18 广州医科大学附属脑科医院 一组用于预测氯胺酮治疗难治性抑郁症的疗效的标志物及其应用

Family Cites Families (165)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2213567C (en) * 1995-02-24 2010-01-26 Stuart L. Weg Use of ketamine for facilitating detoxification and treatment of smoking addiction, and device therefor
GB0009469D0 (en) * 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formalities for use in inhaler devices
US20050148673A1 (en) 2002-07-11 2005-07-07 Harbut Ronald E. Prolonged administration of NMDA antagonist and safener drug to alter neuropathic pain condition
MXPA05000294A (es) 2002-07-30 2005-08-19 Peter Migaly Terapia combinada para la depresion, prevencion de suicidios y varias condiciones medicas y psiquiatricas.
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US8268352B2 (en) 2002-08-05 2012-09-18 Torrent Pharmaceuticals Limited Modified release composition for highly soluble drugs
WO2004045601A1 (en) * 2002-11-18 2004-06-03 Yaupon Therapeutics, Inc. Analgesic uses of norketamine and ketamine/norketamine prodrugs
US10172810B2 (en) 2003-02-24 2019-01-08 Pharmaceutical Productions, Inc. Transmucosal ketamine delivery composition
CA2516619A1 (en) 2003-02-26 2004-09-10 Johns Hopkins University Glutamate transport modulatory compounds and methods
EP1613324A2 (en) 2003-04-14 2006-01-11 Pain Therapeutics, Inc. Methods for the treatment of pain comprising opioid antagonists
WO2005102338A1 (en) 2004-04-20 2005-11-03 Pfizer Limited Method of treating neuropathic pain using a crth2 receptor antagonist
WO2006042249A2 (en) 2004-10-08 2006-04-20 Neuromolecular Pharmaceuticals, Inc. Methods and compositions for treating migraine pain
US20080096872A1 (en) 2004-12-22 2008-04-24 Friedman Robert S Composition for Treatment of Pain Specification
MX2007010721A (es) 2005-03-01 2007-11-13 Pfizer Ltd Nuevo uso de inhibidores de fosfodiesterasa 7 para el tratamiento de dolor neuropatico.
WO2006094797A1 (en) 2005-03-04 2006-09-14 Mentis Cura Ehf. A method and a system for assessing neurological conditions
BRPI0607017B8 (pt) 2005-04-06 2021-05-25 Adamas Pharmaceuticals Inc composição farmacêutica compreendendo memantina e donezepil, e seu uso para o tratamento de condições relacionadas ao snc
GB0523031D0 (en) * 2005-11-11 2005-12-21 Yaupon Therapeutics Enhancement of morphine analgesia by s(-)-norketamine
JP2009520040A (ja) 2005-12-19 2009-05-21 ファーマイン コーポレーション 治療薬の送達のための疎水性コアの担体組成物、及び同担体組成物の作製法及び使用法
JP2009530385A (ja) 2006-03-22 2009-08-27 マウント シナイ スクール オブ メディシン うつ病の治療のためのケタミンの鼻内投与
BRPI0711872A2 (pt) 2006-05-22 2011-12-06 Vanda Pharmaceuticals Inc tratamento para distúrbios depressivos
EP1902733A1 (en) 2006-09-19 2008-03-26 Laboratorios Del Dr. Esteve, S.A. Combination of a NMDA-receptor ligand and a compound with 5-HT6 receptor affinity
EP2114150A4 (en) 2007-02-01 2010-03-10 Alan I Green COMBINATIONS OF BLOCKING OF DOPAMINERGIC D2 RECEPTORS WITH INHIBITION OF NOREPINEPHRINE RECAPTATION AND BLOCKING OF NOREPINEPHRINE ALPHA RECEPTORS
DE102007009888A1 (de) 2007-02-28 2008-09-04 Hermann, Holger Lars, Dr. Verwendung von S-(+)-Ketamin zur Behandlung von Depressionen
LT2125698T (lt) 2007-03-15 2016-10-10 Auspex Pharmaceuticals, Inc. Deuterintas d9-venlafaksinas
WO2008141057A1 (en) 2007-05-08 2008-11-20 Auspex Pharmaceuticals, Inc. Deuterated pimavanserin 1- (4-flu0r0benzyl) -3- (4-isobutoxybenzyl) -1- ( l-methyl-piperidin-4-yl) -urea
US20090004281A1 (en) 2007-06-26 2009-01-01 Biovail Laboratories International S.R.L. Multiparticulate osmotic delivery system
US20100316678A1 (en) 2007-06-28 2010-12-16 Cnsbio Pty Ltd. Combination methods and compositions for treatment of neuropathic pain
CA2698038A1 (en) 2007-07-26 2009-01-29 Entra Pharmaceuticals Inc. Systems and methods for delivering drugs
WO2009021058A2 (en) 2007-08-06 2009-02-12 Trinity Labortories, Inc. Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy
SI2200610T1 (en) 2007-09-21 2018-06-29 Acadia Pharmaceuticals Inc. Co-administration of pimavanserin with other agents
EP2254577A1 (en) 2007-12-26 2010-12-01 Eisai R&D Management Co., Ltd. Ampa receptor antagonists for epilepsy, mental disorders or deficits in sensory organ
US20090198145A1 (en) 2008-02-06 2009-08-06 Chow Harrison Compositions, methods, and systems for rapid induction and maintenance of continuous rem sleep
US20140037718A1 (en) 2009-03-06 2014-02-06 George W. Lutz Transdermal pain gel
GB0908129D0 (en) * 2009-05-12 2009-06-24 Innovata Ltd Composition
US20120225949A1 (en) 2009-08-14 2012-09-06 Demitri Papalos Compositions and methods for treating bipolar disorder
EP2493457B1 (en) 2009-10-30 2017-08-09 IX Biopharma Ltd Fast dissolving solid dosage form
WO2011086563A2 (en) 2010-01-18 2011-07-21 Elminda Ltd. Method and system for weighted analysis of neurophysiological data
WO2013003669A2 (en) 2011-06-30 2013-01-03 University Of South Florida Compositions, methods of use, and methods of treatment
CN104114714A (zh) 2011-12-14 2014-10-22 阿斯利康(瑞典)有限公司 Gabr-a2诊断
US20130236573A1 (en) 2012-03-12 2013-09-12 Janssen Pharmaceutica Nv Esketamine for the treatment of treatment-refractory or treatment-resistant depression
JP2015512418A (ja) 2012-03-30 2015-04-27 ザ ジェネラル ホスピタル コーポレイション うつ病の治療におけるスコポラミンおよびケタミンを含む組成物
US20120323214A1 (en) 2012-05-16 2012-12-20 Totada R Shantha Alzheimer's disease treatment with multiple therapeutic agents delivered to the olfactory region through a special delivery catheter and iontophoresis
WO2014020155A1 (en) 2012-08-02 2014-02-06 Clinpharm Reform Gmbh Oral transmucosal adminstration forms of s-ketamine
SG11201501292UA (en) 2012-08-23 2015-05-28 Stuart L Weg Anxiolytic composition, formulation and method of use
US8974365B2 (en) 2012-11-25 2015-03-10 Steven Richard Devore Best Treatment of thalamocortical dysrhythmia
EP2938608B1 (en) 2012-12-20 2021-08-04 Sanford-Burnham Medical Research Institute Small molecule agonists of neurotensin receptor 1
EP3498268A1 (en) 2013-03-15 2019-06-19 Janssen Pharmaceutica NV Pharmaceutical composition of s-ketamine hydrochloride
PE20200404A1 (es) 2013-03-15 2020-02-26 Janssen Pharmaceutica Nv Composicion farmaceutica de clorhidrato de s-ketamina
AU2014248455B2 (en) 2013-04-01 2018-12-06 Pulmatrix Operating Company, Inc. Tiotropium dry powders
EP3960162A1 (en) 2013-08-26 2022-03-02 Amorsa Therapeutics, Inc. Single-layer oral dose of neuro-attenuating ketamine
WO2015037248A1 (en) 2013-09-13 2015-03-19 National University Corporation Chiba University Application of r-ketamine and salt thereof as pharmaceuticals
US9610259B2 (en) 2014-01-14 2017-04-04 Children's Hospital Medical Center Compositions and methods for treating an autism spectrum disorder
EP3131533B1 (en) 2014-04-17 2019-06-05 Develco Pharma Schweiz AG Oral dosage form of ketamine
KR20220102662A (ko) 2014-05-06 2022-07-20 노쓰웨스턴유니버시티 Nmdar 조절 화합물의 조합물
US11207316B2 (en) 2014-05-30 2021-12-28 West Virginia University Ketamine or dextromethorphan formulations and methods of use
US20160008777A1 (en) 2014-07-09 2016-01-14 Novotec Consulting Inc. Pharmaceutical compounding kit
CA2957926A1 (en) 2014-08-13 2016-02-18 Janssen Pharmaceutica Nv Method for the treatment of depression
KR20170054470A (ko) 2014-09-15 2017-05-17 얀센 파마슈티카 엔.브이. VAL66MET (SNP rs6265) 유전자형 특이적 투여 계획 및 우울증 치료 방법
WO2016057712A1 (en) 2014-10-07 2016-04-14 Lam Therapeutics, Inc. An inhalable rapamycin formulation for the treatment of pulmonary hypertension
EP3215147B1 (en) 2014-11-04 2024-02-28 ACADIA Pharmaceuticals Inc. Neuro-attenuating norketamine compounds and methods
EP3229788A4 (en) 2014-12-08 2018-06-13 Cima Labs Inc. Immediate release abuse-deterrent granulated dosage forms
EP3240422A1 (en) 2014-12-31 2017-11-08 Icahn School of Medicine at Mount Sinai Method of maintaining the anti-depressant effect of ketamine with lithium
US10302625B2 (en) 2015-01-15 2019-05-28 Centre For Addiction And Mental Health Peripheral measure of central brain inflammation, markers therefor and uses thereof
EP3085366A1 (en) 2015-04-22 2016-10-26 Institut du Cerveau et de la Moelle Epiniere-ICM Nmda antagonists for the treatment of mental disorders with occurrence of aggressive and/or impulsive behavior
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
WO2016186968A1 (en) 2015-05-15 2016-11-24 The Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treating motor disorders
US20160338977A1 (en) 2015-05-20 2016-11-24 Janssen Pharmaceutica Nv Methods and kits for treating depression
CA2988578A1 (en) 2015-06-12 2016-12-15 Indiana University Research & Technology Corporation Predicting suicidality using a combined genomic and clinical risk assessment
AU2016288188B2 (en) 2015-06-27 2021-08-05 Shenox Pharmaceuticals, Llc Ketamine transdermal delivery system
CN106562952B (zh) * 2015-10-09 2020-06-09 江阴安博生物医药有限公司 氯胺酮在治疗重性抑郁障碍中的应用
EP3362080A1 (en) 2015-10-16 2018-08-22 Northwestern University Pharmaceutical combination of an atypical antipsychotic and an nmda modulator for the treatment of schizophrenia,bipolar disorder, cognitive impairment and major depressive disorder
WO2017087691A1 (en) 2015-11-17 2017-05-26 The Trustees Of Columbia University In The City Of New York Pharmacological prophylactics against stress-induced affective disorders and their associated symptoms
US10881637B2 (en) 2015-11-17 2021-01-05 Atlee Solomon Intranasal and transdermal administration of kappa-opioid-receptor agonists: salvinorin A for the treatment of neuropsychiatric and addictive disorders
US20180296478A1 (en) 2016-02-12 2018-10-18 Synergistic Therapeutics, Llc Sublingual antidepressant and antianxiety tablet
US20180042936A1 (en) 2016-03-18 2018-02-15 Genomind, Inc. Maintenance therapy using tianeptine
JP2019512528A (ja) 2016-03-25 2019-05-16 ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ 抑うつ、不安症、快感消失症、疲労、自殺念慮、および外傷後ストレス障害の治療における(2r,6r)−ヒドロキシノルケタミンおよび(2s,6s)−ヒドロキシノルケタミンの使用方法
WO2017205666A1 (en) 2016-05-25 2017-11-30 National Health Research Institutes Method and composition for decreasing the psychotomimetic side effect and addictive disorder of ketamine
KR20240027874A (ko) 2016-07-28 2024-03-04 리제너론 파마슈티칼스 인코포레이티드 Gpr156 변이체 및 이들의 용도
CN109640947A (zh) 2016-08-05 2019-04-16 株式会社新日本科学 鼻内药物粉末组合物
US20180064655A1 (en) 2016-09-06 2018-03-08 Steven Sounyoung Yu Hydroxynorketamine Transdermal Patch
US10596378B2 (en) 2016-10-18 2020-03-24 Joseph Rustick Method for treatment of depression using synaptic pathway training
US10905897B2 (en) 2016-10-20 2021-02-02 Neuro-Laser Foundation, Inc. Synergistic treatment methodologies using light therapy
IL315066A (en) 2016-10-27 2024-10-01 Univ Chiba Nat Univ Corp Application of (s)-norketamine and salt therof as pharmaceutical
US20180177743A1 (en) 2016-12-22 2018-06-28 Gary Jay Method of treating pain using racemic mixture of s-ketamine and r-ketamine
US20180177744A1 (en) 2016-12-22 2018-06-28 Gary Jay Method of treating pain and depression using a hybrid mixture of s-ketamine and r-ketamine
AU2018254506A1 (en) 2017-04-20 2019-10-31 Guangzhou Dazhou Biomedicine Ltd. Transdermal drug delivery system for ketamine
EP3635130A4 (en) 2017-05-12 2021-06-09 Indiana University Research and Technology Corporation Precision medicine for treating and preventing suicidality
MX394876B (es) 2017-05-25 2025-03-24 Glytech Llc Formulaciones para el tratamiento del trastorno de estres post-traumatico.
DE102017112527B4 (de) 2017-06-07 2019-01-03 Lts Lohmann Therapie-Systeme Ag Schnell zerfallende Schaumwafer mit hohem Flächengewicht
WO2018234568A2 (en) 2017-06-23 2018-12-27 Develco Pharma Schweiz Ag Hydroxynorketamine for the use in the treatment of depression
WO2019038756A1 (en) 2017-08-20 2019-02-28 Solubest Ltd. DRY POWDER COMPOSITIONS FOR INTRANASAL DELIVERY
ES2924188T3 (es) 2017-09-25 2022-10-05 Small Pharma Ltd Formas sólidas de dosificación oral de derivados de ketamina
TW201919595A (zh) 2017-09-27 2019-06-01 國立大學法人千葉大學 作為神經變性疾病或認知機能障礙之預防或治療劑之r-氯胺酮及其衍生物
US12090123B2 (en) 2017-10-10 2024-09-17 Douglas Pharmaceuticals Ltd. Extended release pharmaceutical formulation
WO2019079742A1 (en) 2017-10-19 2019-04-25 Eleusis Benefit Corporation, Pbc METHODS AND SYSTEMS FOR IMPROVING THE SAFETY OF PSYCHEDELIC PHARMACOTHERAPIES
US11491120B2 (en) 2017-11-09 2022-11-08 The Trustees Of Columbia University In The City Of New York Pharmacological prophylactics against stress-induced affective disorders in females
US20200384188A1 (en) 2017-11-14 2020-12-10 Bexson Biomedical, Inc. Systems, devices, formulations and methods for controlled drug delivery
DE102017129012A1 (de) 2017-12-06 2019-06-06 Lts Lohmann Therapie-Systeme Ag Oraler Dünnfilm mit hoher Wirkstoffbeladung
IL275482B1 (en) 2017-12-22 2025-03-01 Janssen Pharmaceuticals Inc Esketamine for the treatment of depression
EP3505157B1 (en) 2017-12-29 2021-12-08 Celon Pharma S.A. Dry powder ketamine composition for pulmonary administration in treatment-resistant depression
RU2756512C1 (ru) 2018-01-10 2021-10-01 ЭксДабл-ЮФАРМА ЛТД. Пролекарства кетамина, его композиции и применения
JP7354123B2 (ja) 2018-02-21 2023-10-02 エイアイ・セラピューティクス・インコーポレーテッド アピリモドとグルタミン酸作動薬を用いた併用療法
US11980617B2 (en) 2018-03-16 2024-05-14 Intra-Cellular Therapies, Inc. Methods of treating acute depression and/or acute anxiety
WO2019186357A1 (en) 2018-03-26 2019-10-03 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
US20230390385A1 (en) 2018-04-11 2023-12-07 Fred M. COWAN Compositions and Methods for Prevention and Treatment of Immune Complex Disease
EP3813808A4 (en) 2018-05-04 2022-01-26 Perception Neuroscience, Inc. Methods of treating substance abuse
US11766409B2 (en) 2018-05-31 2023-09-26 The University Of Queensland Core-shell polymer nanoparticle
GB201809976D0 (en) 2018-06-18 2018-08-01 Neurocentrx Pharma Ltd Novel formulations
EP3813807A1 (en) 2018-06-27 2021-05-05 Clexio Biosciences Ltd. Method of treating major depressive disorder
CN115154440A (zh) 2018-06-27 2022-10-11 比奥克斯塞尔医疗股份有限公司 含右美托咪定的膜制剂及其制造方法
CN112512509A (zh) 2018-08-02 2021-03-16 台湾微脂体股份有限公司 含有治疗抑郁症或焦虑症的治疗剂的缓释组合物及其用途
US20200038420A1 (en) 2018-08-03 2020-02-06 Enterin, Inc. Aminosterol compositions and methods of using the same for treating depression
US11154537B2 (en) 2018-08-10 2021-10-26 Eleusis Therapeutics Us, Inc. Method of treatment for ketamine infusion
US12090145B2 (en) 2018-08-20 2024-09-17 Yale University Combination therapy for treating or preventing depression or other mood diseases
EP3628313B1 (en) * 2018-09-28 2025-02-12 Novohale Therapeutics, LLC Ketamine composition for use in a method of treatment of depression by pulmonary administration
US20210113494A1 (en) 2018-10-05 2021-04-22 Clexio Biosciences Ltd. Method Of Treating Post-Traumatic Stress Syndrome
US20210308040A1 (en) 2018-10-26 2021-10-07 Guangzhou Dazhou Biomedicine Ltd. Ketamine oral transmucosal delivery system
EP3873447A1 (en) 2018-10-29 2021-09-08 Hadasit Medical Research Services and Development Ltd. Combination of m-opioid receptor (mor) modulators for preventing and treating pain, suicidality and mental disorders
MX2021005992A (es) 2018-11-21 2021-09-14 Certego Therapeutics Inc Gaboxadol para reducir el riesgo de suicidio y para alivio rápido de la depresión.
US11981617B2 (en) 2019-01-11 2024-05-14 Alar Pharmaceuticals Inc. Ketamine pamoate and use thereof
CN113632174B (zh) 2019-01-23 2025-03-25 密歇根大学董事会 用于nmda、甘氨酸和ampa受体的调节剂的药物基因组学决策支持
US20200261422A1 (en) 2019-02-15 2020-08-20 Massachusetts Institute Of Technology Methods for evaluating treatments and physiology in human patients using intravenous alpha-2 adrenergic antagonist agents
WO2020178653A1 (en) 2019-03-05 2020-09-10 Janssen Pharmaceuticals, Inc. Esketamine for the treatment of depression
EP4230195A1 (en) 2019-03-07 2023-08-23 Arbormentis LLC Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic / psychotomimetic dosages and formulations
US20220143147A1 (en) 2019-03-18 2022-05-12 New York Medical College Intranasal neuropeptides for use in stress-related impairments
JP7453994B2 (ja) 2019-04-17 2024-03-21 エルテーエス ローマン テラピー-ジステーメ アーゲー 経皮治療システム
WO2020223701A1 (en) 2019-05-02 2020-11-05 The Broad Institute, Inc. Methods for treating neurodevelopmental disorders
US20220202742A1 (en) 2019-05-07 2022-06-30 Clexio Biosciences Ltd. Dosage forms for preventing drug-facilitated assault
US20220062200A1 (en) 2019-05-07 2022-03-03 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
JP2022541872A (ja) 2019-05-31 2022-09-28 セロン ファーマ エス.アー. 医薬組成物の電子的に監督された非経口投与のための吸入器
KR20220012922A (ko) 2019-05-31 2022-02-04 셀론 파르마 에스.에이. 약학적 조성물의 전자적으로 관리된 투여
US20220257536A1 (en) 2019-06-04 2022-08-18 ADNP Kids Research Foundation Ketamine and ketamine/nap for treatment of adnp syndrome and related neurological conditions
WO2021026232A1 (en) 2019-08-05 2021-02-11 The Ketamine Research Foundation Ketamine for the treatment of postpartum symptoms and disorders
CN114286674A (zh) 2019-08-28 2022-04-05 杨森制药公司 用于治疗患有包括自杀倾向在内的重性抑郁障碍的患者的艾司氯胺酮
GB201912505D0 (en) 2019-08-30 2019-10-16 Klaria Pharma Holding Ab Pharmaceutical formulation
EP4028085A4 (en) 2019-09-13 2023-10-04 Janssen Pharmaceuticals, Inc. INTRANASAL ADMINISTRATION OF ESKETAMINE
MX2022004022A (es) 2019-10-02 2022-05-18 Praxis Prec Medicines Inc Combinaciones de moduladores alostericos positivos del receptor de gaba-a y antagonistas de nmda, moduladores alostericos negativos de nmda o agonistas parciales de nmda.
WO2021074448A1 (en) 2019-10-18 2021-04-22 Institute Of Science And Technology Austria Stimulation of neuronal plasticity
WO2021087258A1 (en) 2019-10-31 2021-05-06 The Trustees Of Indiana University Compositions and methods for treating alcohol use disorder or a related condition thereof
WO2021108801A2 (en) 2019-11-15 2021-06-03 Consegna Pharma, Inc. Long acting nmda antagonists
AU2020387937A1 (en) 2019-11-18 2022-06-02 The United States Government As Represented By The Department Of Veterans Affairs Salts of (2R, 6R)-hydroxynorketamine, their crystal forms, and methods of making the same
WO2021101926A1 (en) 2019-11-19 2021-05-27 Stamets Paul Edward Tryptamine compositions for enhancing neurite outgrowth
TW202135787A (zh) 2019-12-12 2021-10-01 比利時商健生藥品公司 艾氯胺酮調配物及製備與儲存的方法
WO2021121366A1 (en) 2019-12-20 2021-06-24 Alar Pharmaceuticals Inc. Long-acting injectable formulations of ketamine pamoate salts
JP2023507926A (ja) 2019-12-30 2023-02-28 クレキシオ バイオサイエンシーズ エルティーディー. 神経精神状態または神経学的状態を治療するためのエスケタミンを用いた投与計画
IL293506A (en) 2019-12-30 2022-08-01 Clexio Biosciences Ltd Dosage regime with esketamine for treating major depressive disorder
CN115135317A (zh) 2020-01-22 2022-09-30 西洛斯治疗有限公司 减少nmda拮抗剂的副作用
DE102020106115A1 (de) 2020-03-06 2021-09-09 Lts Lohmann Therapie-Systeme Ag Iontophoretische Zusammensetzung zur Verabreichung von S-Ketamin
US20210308075A1 (en) 2020-04-07 2021-10-07 Joseph Habboushe Prevention and treatment of virial infections
IL298334A (en) 2020-05-20 2023-01-01 Certego Therapeutics Inc Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders
CA3180964A1 (en) 2020-06-02 2021-12-09 Yip Hang Eddy Lee Methods for treating major depressive disorder and treatment-resistant depression
WO2021255522A1 (en) 2020-06-19 2021-12-23 Guangzhou Dazhou Biomedicine Ltd. Transdermal drug delivery system for ketamine
US20210401774A1 (en) 2020-06-27 2021-12-30 Robert Brent Turnipseed Ketamine protocols and data evaluation for treatment-resistant depression and trauma
US20220001014A1 (en) 2020-07-01 2022-01-06 Lida Ghaderi Compositions and methods for inducing biological mimicry in a mammal for the prevention and/or treatment of covid-19 and other diseases
US20220040106A1 (en) 2020-08-05 2022-02-10 Thomas Malcolm Tailored hypoimmune nanovesicular delivery systems for cancer tumors, hereditary and infectious diseases
EP3949956A1 (en) 2020-08-06 2022-02-09 LTS Lohmann Therapie-Systeme AG Esketamine-suspension-tts
JP2023538901A (ja) 2020-08-18 2023-09-12 オークウッド ラボラトリーズ,エル.エル.シー. ケタミンを含むマイクロスフェア製剤ならびにその製造及び使用方法
US20230375561A1 (en) 2020-09-30 2023-11-23 Rima F. Kaddurah-Daouk Methods for identification, stratification, and treatment of cns diseases
EP3995137B1 (de) 2020-11-09 2024-01-03 LTS Lohmann Therapie-Systeme AG Oraler dünnfilm
US20230420110A1 (en) 2020-11-18 2023-12-28 Indiana University Research And Technology Corporation Methods for objective assessment, risk prediction, matching to existing medications and new methods of using drugs, and monitoring responses to treatments for mood disorders
US11382873B1 (en) 2021-01-08 2022-07-12 Vitalis Analgesics LLC Oral administration of ketamine
IL282188A (en) 2021-04-08 2022-11-01 Yeda Res & Dev Combined use of ketamine and bretigabine for the treatment of psychiatric disorders
US11690811B2 (en) 2021-08-13 2023-07-04 XWPharma Ltd. Pharmaceutical compositions and oral dosage forms of ketamine derivatives
WO2023081109A1 (en) 2021-11-05 2023-05-11 Malcolm Thomas Tailored hypoimmune nanovesicular delivery systems for cancer tumors, hereditary and infectious diseases
US20240009145A1 (en) 2022-07-07 2024-01-11 Vitalis Analgesics LLC Compositions of aspirin and ketamine

Similar Documents

Publication Publication Date Title
AU2025204271A1 (en) Microcrystalline diketopiperazine compositions and methods
JP2021510682A5 (enExample)
ES2613754T3 (es) Uso de glicopirrolato para tratar la taquicardia
JP2016512494A5 (enExample)
RU2014150422A (ru) Новая дозировка и препаративная форма
JP2020514412A5 (enExample)
JP2015519356A5 (enExample)
JP2016515576A5 (enExample)
RU2014140674A (ru) Новая дозировка и препаративная форма
WO2010097115A1 (en) Pharmaceutical formulations comprising 4-{(1r)-2- [(6-{2-[(2,6-dichlorobenzyl)oxy] ethoxy}hexyl)amino]-1-hydroxyethyl}-2- (hydroxymethyl)phenol
RU2016117764A (ru) Рапамицин для лечения лимфангиолейомиоматоза
JP7021078B2 (ja) ニコチンをベースとする乾燥粉末製剤のきつさを制御するためのシステムおよび方法
EA201591869A1 (ru) Композиция, содержащая для повышения стабильности лекарственной формы по меньшей мере два сухих порошка, получаемых распылительной сушкой
HK1203149A1 (en) Novel dosage form and formulation of abediterol
PT1545634E (pt) Método para preparar composições de pó seco para inalação
CA2838030A1 (en) Combination comprising umeclidinium and a corticosteroid
JP2017534604A5 (enExample)
CA3144713A1 (en) Pharmaeutical composition comprising ensifentrine
JP2018527386A (ja) ニコチン製剤、ならびにこれを作製および使用する方法
JP2018537453A5 (enExample)
MX2017004476A (es) Composicion que comprende al menos un polvo seco obtenido por secado por atomizacion para aumentar la estabilidad de la formulacion.
CA2838031A1 (en) Dry powder inhaler compositions comprising umeclidinium
JP5501451B2 (ja) 咳の治療のためのテオブロミン
EP2821062A1 (en) Novel dry powder inhaler formulations
EP2957552B1 (en) Vilanterol formulations